Silent Graft Occlusion After CABG Complicates Heart Care
In-hospital silent asymptomatic graft occlusion following coronary artery bypass grafting (CABG) was associated with an increased incidence of angina-related rehospitalisations and reinterventions after 1 year of follow-up.
METHODOLOGY:
Silent CABG occlusion occurs in 5%-17% of patients after surgery and often goes undetected due to the absence of any classic signs of myocardial infarction, posing major challenges for diagnosis and management.
Researchers analysed data from a prospective cohort study including 292 patients (mean age, 67 years; 85% men) who underwent isolated CABG between July 2021 and December 2023 to assess mid-term outcomes in those with early silent CABG occlusion.
Silent CABG occlusion was defined as occlusion detected using coronary CT before discharge from the hospital and without any clinical signs of perioperative myocardial infarction.
Patients received standard care, including anticoagulation and dual antiplatelet therapy, after operation and completed follow-up of at least 1 year.
The primary endpoint was the incidence of angina-related rehospitalisations and coronary revascularisations over a mean follow-up duration of 14.5 months.
TAKEAWAY:
Silent in-hospital CABG occlusion was identified in 8.5% of patients, and these patients had a longer hospital stay than those without silent CABG occlusion (median, 10 vs 8 days; P < .001).
Patients with silent CABG occlusion had a higher incidence of angina-related rehospitalisations (28% vs 4.1%; P < .01) and reinterventions (28% vs 2.6%; P < .01) than those without silent CABG occlusion.
Graft occlusion was associated with a nearly 8.5-fold higher risk for rehospitalisation and a 15-fold higher risk for reintervention (P < .001 for both).
Overall mortality or rates of major adverse cardiovascular and cerebrovascular events did not differ significantly between patients with and without silent CABG occlusion.
IN PRACTICE:
"Our findings support the routine use of postoperative cCT [coronary CT] angiography to identify silent graft occlusions, which are frequently underdiagnosed with symptom-driven follow-up alone; early detection enables tailored risk stratification, facilitates ischaemia testing when indicated and informs closer surveillance rather than reflexive intervention," the researchers noted.
SOURCE:
This study was led by Islam Salikhanov, MD, PhD, University Hospital Basel, Basel, Switzerland. It was published online on July 07, 2025, in Open Heart.
LIMITATIONS:
This study was conducted at a single centre. The incidence of silent graft occlusion was 8.5%, which limited the statistical power for subgroup analyses. The exclusion of patients with severe renal issues or iodine-contrast allergies limited the generalisability of the findings.
DISCLOSURES:
This study received funding from the Immanuel and Ilse Straub Foundation. The authors declared having no conflicts of interest.
This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
an hour ago
- Yahoo
A cancer diagnosis can cause out-of-pocket costs to surge, study finds
A cancer diagnosis increases privately insured patients' monthly out-of-pocket costs, which also rise as the disease progresses, new research shows. Out-of-pocket costs jumped by $592.53 per month for the six months after a diagnosis, according to a recent report published in JAMA Open Network. The study underscores the financial toll a cancer diagnosis can take on individuals, even for those who are insured but don't yet qualify for Medicare. While cancer tends to strike later in life, when most patients in treatment are receiving Medicare benefits, a cancer diagnosis can pose an undue financial burden on younger people with private insurance, the report found. Those out-of-pocket costs highlight the need for policy reform, the report said. The research "underscores the need for policies such as paid sick leave that address both insurance continuity and financial assistance, especially for patients with more advanced cancer," the report states. Out-of-pocket costs increased based on a patient's cancer progression, the analysis found. Patients with stage 0 cancer saw their costs rise by $462 per month compared to non-cancer patients, while stage 4 cancer cost people with private insurance an additional $719.97 per month in out of pocket costs. Costs rise as the disease progresses because patients typically require more treatment during cancer's later stages, leading to greater medical expenditures. "This result seems straightforward; later-stage disease is associated with more intensive workup and treatment that can drive higher medical expenditures," the report states. Researchers analyzed medical claims records from the Surveillance, Epidemiology, and End Results (SEER) cancer registry to compare the out-of-pocket costs of privately insured individuals under the age of 65 who were diagnosed with breast, colorectal, and lung cancer, to those without cancer. New research from the American Cancer Society shows that as more people aged 45-49 undergo screening for colon cancer, more early stage diagnoses are being made. DOGE savings are a fraction of what the department claims, CBS News analysis finds Details on House subpoenas for Clintons and others over Epstein files Trump doubles down on decision to fire labor statistics chief Solve the daily Crossword
CBS News
an hour ago
- CBS News
A cancer diagnosis can cause out-of-pocket costs to surge, even for those with insurance
A cancer diagnosis increases privately insured patients' monthly out-of-pocket costs, which also rise as the disease progresses, new research shows. Out-of-pocket costs jumped by $592.53 per month for the six months after a diagnosis, according to a recent report published in JAMA Open Network. The study underscores the financial toll a cancer diagnosis can take on individuals, even for those who are insured but don't yet qualify for Medicare. While cancer tends to strike later in life, when most patients in treatment are receiving Medicare benefits, a cancer diagnosis can pose an undue financial burden on younger people with private insurance, the report found. Those out-of-pocket costs highlight the need for policy reform, the report said. The research "underscores the need for policies such as paid sick leave that address both insurance continuity and financial assistance, especially for patients with more advanced cancer," the report states. Out-of-pocket costs increased based on a patient's cancer progression, the analysis found. Patients with stage 0 cancer saw their costs rise by $462 per month compared to non-cancer patients, while stage 4 cancer cost people with private insurance an additional $719.97 per month in out of pocket costs. Costs rise as the disease progresses because patients typically require more treatment during cancer's later stages, leading to greater medical expenditures. "This result seems straightforward; later-stage disease is associated with more intensive workup and treatment that can drive higher medical expenditures," the report states. Researchers analyzed medical claims records from the Surveillance, Epidemiology, and End Results (SEER) cancer registry to compare the out-of-pocket costs of privately insured individuals under the age of 65 who were diagnosed with breast, colorectal, and lung cancer, to those without cancer. New research from the American Cancer Society shows that as more people aged 45-49 undergo screening for colon cancer, more early stage diagnoses are being made.
Entrepreneur
3 hours ago
- Entrepreneur
Don't Just Sell Video Visits: Build a Healthtech Revenue Engine
What we learned at a high cost is that telehealth is not just about video visits, but about establishing a scalable revenue model. Opinions expressed by Entrepreneur contributors are their own. Before founding Bask Health, my brother and I once pitched a telehealth startup idea to a VC with a 40-slide deck and a "disrupt healthcare" tagline. He stared at us like we were pitching a smoothie truck. Turns out, nobody cares how "virtual" your care is if you can't explain your revenue model in under 30 seconds. That was a $22,000 lesson in developer costs, regulatory hurdles and hubris. So here's what we wish someone had told us on day one: you're not selling video calls, you're building a real business. In 2025, that means more than convenience. It means unit economics that hold up, multiple buyers beyond just patients and infrastructure that doesn't implode at scale. Below, we'll break down the four core revenue pillars in modern telehealth and how to stress-test each one before you burn through your seed round. Join top CEOs, founders and operators at the Level Up conference to unlock strategies for scaling your business, boosting revenue and building sustainable success. The Nut Graf Telehealth businesses built for 2025 and beyond can't survive on DTC visits alone. The ones that scale combine four revenue streams: Direct-to-Consumer, Employer, Payor and Ancillary, into a model that balances margin, compliance and demand. Here's how to structure yours and how to kill what isn't working, fast. 1. Don't just sell to patients: Land the employer account When we built our first virtual clinic, we assumed individuals would pay out of pocket for convenience. They did, but not in the volumes needed to cover CAC. The real ROI showed up when we signed our first self-insured employer. That one deal brought in 3x the monthly revenue of our entire DTC base. It was the clearest signal we'd seen: B2B revenue can subsidize your B2C growth. What works: Target companies struggling with chronic care costs or absenteeism.; Bundle care options: behavioral health, dermatology, menopause, etc.. Offer reporting dashboards and custom onboarding. Watch for: Stay HIPAA-compliant and FMLA-aware, especially if you're integrating with existing employer EAPs; Procurement cycles that take forever if you don't have a warm intro. Expect to hire B2B sales muscle early, or founder-led selling won't scale. Related: Healthtech Is the New Healthcare 2. Payor reimbursement is a slow game. Play it anyway We avoided insurance in the early days. Too slow. Too complex. But here's the truth: the payor model is hard to start and impossible to ignore. Yes, CMS still reimburses for telehealth, but the rules shift constantly. In 2025, audio-only visits are covered under limited conditions. Some CPT codes only apply to rural areas. And even if you're eligible, collecting payment is a marathon of prior auths and claim resubmissions. What works: Start small: pilot with Medicaid MCOs or carve-outs; Get surgical with your billing codes (RTM, CCM, POS-10, etc.); Hire someone who lives in your state's MAC guidance. Watch for: 60–90 day payment cycles (prepare your burn rate accordingly); Denials for bad documentation or misused modifiers; Overestimating what "covered by insurance" actually means. Related: Why Entrepreneurs Can't Rely on Traditional Retirement Plans (And What to Do Instead) 3. Ancillary services make or break unit economics We once sold $49 telehealth visits with a $120 CAC. It was cute until we looked at our bank account. We fixed it by integrating ancillary services, labs, pharmacy delivery, diagnostics, which turned $49 tickets into $149+. Patients don't want five apps. They want one seamless care journey. Bundling services increases LTV, improves outcomes, and gives you new margin layers to play with. What works: Partner with compounding pharmacies and lab networks. Use API-first infrastructure to automate fulfillment. Track where the drop-off happens between consultation and care. Watch for: State-specific lab-direct and prescribing laws; Ongoing logistics management (especially for shipping); Upfront build time, your developers will hate this unless you buy instead of build. 4. Stress-test your margins with this 4P matrix Before we launch any new care line, we run it through what we call the 4P Matrix: Category questions to ask Patient: Who pays? Individual, employer, or insurer? Payor: Which CPT codes or bundles apply? What's reimbursable? Partner: Are there labs, pharmacies, or vendors to integrate with? Peripherals: What are the add-ons? (RPM, async care, diagnostics?) If any one "P" is weak, you'll feel it in your burn rate within 60 days. If two are weak, you're bleeding cash. And if you can't tighten the loop within one quarter, sunset the service. Don't pitch telehealth. Pitch an economic engine. Investors don't want to hear about your "care journey." Employers don't care how empathetic your UI is. And patients? They want outcomes, fast. If you want to build a profitable telehealth company in 2025: Get clear on who pays and why. Design services that integrate seamlessly. Obsess over margin layers, not marketing buzzwords; And for the love of Wi-Fi, don't duct-tape your HIPAA compliance. Telehealth isn't a shortcut; it's infrastructure. But if you build it right, you're not just riding a trend. You're building healthcare's new backbone.
